Almost a century of science and knowledge backs us.At Reig Jofre, we understand innovation as the driving force behind progress in health. Our commitment translates into the creation of healthcare solutions that combine scientific know- how, cutting-edge pharmaceutical technology, and the ability to collaborate with a global ecosystem of talent and knowledge.
Our Approach
Innovation is part of our DNA. It is not only about science, but about turning ideas into products and services that reach the market and generate a real impact on health. We are committed to achieving clinical advances that improve patients’ lives and promote universal and sustainable access to healthcare systems, always with a vision rooted in science — the foundation of everything we do — as well as safety and quality.
What Makes Us Unique
Innovation in specialised industrial technology
Reig Jofre has cutting-edge know-how and production infrastructures that allow us to develop and manufacture innovative solutions through technological platforms that accelerate development efficiently, safely, and on a scalable basis. This technological capability positions us as a company prepared to produce the medicines of the future.
Innovation in product and brand
At Reig Jofre, innovation in product and portfolio focuses on identifying and developing solutions that bring differential value both to healthcare systems and to patients, combining science, technology, innovative formulations, and new approaches in the hospital setting.
We focus on our therapeutic areas and brands, and we aim to grow with a portfolio of products with greater added value, integrating essential medicines with new presentations and technologies that strengthen our competitive position on a global scale.
Over the years, we have maintained sustained investment in R&D&I, which has enabled us to develop, expand, and diversify our portfolio, internationalise it, and deliver greater value both to patients and to healthcare professionals, reaching our subsidiaries and the wider world through distribution agreements.
Strategic Collaboration
Our model of innovation is built on collaboration. Our active engagement with the healthcare ecosystem enables us to establish strategic partnerships with research centres, technology hubs, and innovative start-ups that complement our capabilities and transform scientific and technological innovation into real solutions for patients.
Examples include the joint venture with LeanBio (Syna Therapeutics), created in 2018 for the development and production of biosimilars; the agreement with the University of Santiago de Compostela for the development of Dexulac, an innovative product for onychomycosis; as well as our participation in several European initiatives such as the Important Project of Common European Interest (IPCEI) in Health, Med4Cure, a strategic project involving multiple countries, designed to enhance research and the development of healthcare industrial capacities across Europe.
A Purpose-Driven Vision
Our innovation is guided by a principle: bringing forward innovative scientific solutions with clinical impact in our areas of expertise, while ensuring accessibility in order to maximise their impact on health. Every project, every collaboration, and every advance is oriented towards addressing real needs, building a healthier and more accessible future for all.
